BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34906988)

  • 1. Variant Identification in BARD1, PRDM9, RCC1, and RECQL in Patients with Ovarian Cancer by Targeted Next-generation Sequencing of DNA Pools.
    Suszynska M; Ratajska M; Galka-Marciniak P; Ryszkowska A; Wydra D; Debniak J; Jasiak A; Wasag B; Cybulski C; Kozlowski P
    Cancer Prev Res (Phila); 2022 Mar; 15(3):151-160. PubMed ID: 34906988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer.
    Ramus SJ; Song H; Dicks E; Tyrer JP; Rosenthal AN; Intermaggio MP; Fraser L; Gentry-Maharaj A; Hayward J; Philpott S; Anderson C; Edlund CK; Conti D; Harrington P; Barrowdale D; Bowtell DD; Alsop K; Mitchell G; ; Cicek MS; Cunningham JM; Fridley BL; Alsop J; Jimenez-Linan M; Poblete S; Lele S; Sucheston-Campbell L; Moysich KB; Sieh W; McGuire V; Lester J; Bogdanova N; Dürst M; Hillemanns P; ; Odunsi K; Whittemore AS; Karlan BY; Dörk T; Goode EL; Menon U; Jacobs IJ; Antoniou AC; Pharoah PD; Gayther SA
    J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26315354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer.
    Weber-Lassalle N; Borde J; Weber-Lassalle K; Horváth J; Niederacher D; Arnold N; Kaulfuß S; Ernst C; Paul VG; Honisch E; Klaschik K; Volk AE; Kubisch C; Rapp S; Lichey N; Altmüller J; Lepkes L; Pohl-Rescigno E; Thiele H; Nürnberg P; Larsen M; Richters L; Rhiem K; Wappenschmidt B; Engel C; Meindl A; Schmutzler RK; Hahnen E; Hauke J
    Breast Cancer Res; 2019 Apr; 21(1):55. PubMed ID: 31036035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Association between single nucleotide polymorphism of BARD1 gene and BRCA1 gene mutation in epithelial ovarian cancer].
    Liu WL; Zhao JZ; Wang ZZ; Dong B; Hou YY; Wu XX; Guo YJ
    Zhonghua Fu Chan Ke Za Zhi; 2017 Jun; 52(6):403-410. PubMed ID: 28647964
    [No Abstract]   [Full Text] [Related]  

  • 5. Apparent regional differences in the spectrum of BARD1 pathogenic variants in Spanish population and importance of copy number variants.
    Benito-Sánchez B; Barroso A; Fernández V; Mercadillo F; Núñez-Torres R; Pita G; Pombo L; Morales-Chamorro R; Cano-Cano JM; Urioste M; González-Neira A; Osorio A
    Sci Rep; 2022 May; 12(1):8547. PubMed ID: 35595798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical implications of germline mutations in breast cancer genes: RECQL.
    Bowden AR; Tischkowitz M
    Breast Cancer Res Treat; 2019 Apr; 174(3):553-560. PubMed ID: 30610487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Literature Review of
    Alenezi WM; Fierheller CT; Recio N; Tonin PN
    Genes (Basel); 2020 Jul; 11(8):. PubMed ID: 32726901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FANCM and RECQL genetic variants and breast cancer susceptibility: relevance to South Poland and West Ukraine.
    Nguyen-Dumont T; Myszka A; Karpinski P; Sasiadek MM; Akopyan H; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Kitsera N; Siekierzynska A; Southey MC
    BMC Med Genet; 2018 Jan; 19(1):12. PubMed ID: 29351780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Rofes P; Del Valle J; Torres-Esquius S; Feliubadaló L; Stradella A; Moreno-Cabrera JM; López-Doriga A; Munté E; De Cid R; Campos O; Cuesta R; Teulé Á; Grau È; Sanz J; Capellá G; Díez O; Brunet J; Balmaña J; Lázaro C
    Genes (Basel); 2021 Jan; 12(2):. PubMed ID: 33498765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of large mutations in BARD1 in patients with breast and/or ovarian cancer: the Polish population as an example.
    Klonowska K; Ratajska M; Czubak K; Kuzniacka A; Brozek I; Koczkowska M; Sniadecki M; Debniak J; Wydra D; Balut M; Stukan M; Zmienko A; Nowakowska B; Irminger-Finger I; Limon J; Kozlowski P
    Sci Rep; 2015 May; 5():10424. PubMed ID: 25994375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer predisposing BARD1 mutations in breast-ovarian cancer families.
    Ratajska M; Antoszewska E; Piskorz A; Brozek I; Borg Å; Kusmierek H; Biernat W; Limon J
    Breast Cancer Res Treat; 2012 Jan; 131(1):89-97. PubMed ID: 21344236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and characterization of missense alterations in the BRCA1 associated RING domain (BARD1) gene in breast and ovarian cancer.
    Sauer MK; Andrulis IL
    J Med Genet; 2005 Aug; 42(8):633-8. PubMed ID: 16061562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline mutations of the BRCA1-associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations.
    Ghimenti C; Sensi E; Presciuttini S; Brunetti IM; Conte P; Bevilacqua G; Caligo MA
    Genes Chromosomes Cancer; 2002 Mar; 33(3):235-42. PubMed ID: 11807980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next Generation Sequencing-Based Germline Panel Testing for Breast and Ovarian Cancers in Pakistan.
    Tariq H; Gul A; Khadim T; Ud-Din H; Tipu HN; Asif M; Ahmed R
    Asian Pac J Cancer Prev; 2021 Mar; 22(3):719-724. PubMed ID: 33773534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional analysis of clinical
    Toh MR; Chong ST; Chan SH; Low CE; Ishak NDB; Lim JQ; Courtney E; Ngeow J
    Cold Spring Harb Mol Case Stud; 2019 Aug; 5(4):. PubMed ID: 31371347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted next-generation sequencing of 21 candidate genes in hereditary ovarian cancer patients from the Republic of Bashkortostan.
    Prokofyeva DS; Mingazheva ET; Valova YV; Sakaeva DD; Faishanova RR; Nurgalieva AK; Valiev RR; Bogdanova N; Dörk T; Khusnutdinova EK
    J Ovarian Res; 2023 Apr; 16(1):66. PubMed ID: 37013556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
    Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
    Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancing the BOADICEA cancer risk prediction model to incorporate new data on
    Lee A; Mavaddat N; Cunningham A; Carver T; Ficorella L; Archer S; Walter FM; Tischkowitz M; Roberts J; Usher-Smith J; Simard J; Schmidt MK; Devilee P; Zadnik V; Jürgens H; Mouret-Fourme E; De Pauw A; Rookus M; Mooij TM; Pharoah PP; Easton DF; Antoniou AC
    J Med Genet; 2022 Dec; 59(12):1206-1218. PubMed ID: 36162851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers.
    Rebbeck TR; Mitra N; Domchek SM; Wan F; Chuai S; Friebel TM; Panossian S; Spurdle A; Chenevix-Trench G; ; Singer CF; Pfeiler G; Neuhausen SL; Lynch HT; Garber JE; Weitzel JN; Isaacs C; Couch F; Narod SA; Rubinstein WS; Tomlinson GE; Ganz PA; Olopade OI; Tung N; Blum JL; Greenberg R; Nathanson KL; Daly MB
    Cancer Res; 2009 Jul; 69(14):5801-10. PubMed ID: 19584272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.